ClinicalTrials.gg
RecruitingNCT07018752PlaTformUpdated Nov 12, 2026

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

A Phase 1/2 interventional study of roginolisib and golcadomide in Peripheral T Cells Lymphoma (PTCL) and Follicular Helper T-Cell Lymphoma, sponsored by The Lymphoma Academic Research Organisation. Recruiting at 20 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by The Lymphoma Academic Research Organisation · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Nov 6, 2026Site recruiting status changedEnrollment updated+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 237 studies in Lymphoma with a site in France — 33 open to participants now, 54 under way, 11 of them phase 3. Lymphoma · France.

Planned enrollment
122nd of 199
80 · median 110
Started
2025
with 6 others
Phase 1/2
27 of 237
9 open now
Primary completion
2028-04
later than 38 of 53 live
Registered
236th of 237
by date
Lead sponsor
7 of 237
The Lymphoma Academic Research Organisation

Among the 237 studies in Lymphoma with a site in France, this one is the 122nd largest by planned enrollment of the 199 interventional ones that give a count, is one of 7 that started in 2025, is one of 27 in phase 1/2, reaches primary completion later than 38 of the 53 other live ones, and was the 236th registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

33 of the 237 studies in Lymphoma with a site in France are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 237 studies in Lymphoma with a site in France, or all of them as a file.
02

Study summary

This study is a platform trial for the evaluation of new drugs or combination of drugs in relapsed or refractory peripheral T-cell lymphomas.

The objective of the study is to generate exploratory data on new drugs or combination of drugs to treat refractory/relapse peripheral T-cells lymphoma to better identify the population of interest and design future correct clinical trials.

Primary objectives of the different sub-studies :

  • phase 1 sub-studies: determine the safety and tolerability of escalating doses of the sub-study treatment
  • phase 2 sub-studies: identify drugs that will improve significantly the outcome in target patients Secondary objectives of all sub-studies: analyze the response rate, the clinical benefit rate, the progression-free survival, the duration of response, the time to next treatment or death, the overall survival, the rate of transplantation following study treatment and the safety profile of the drugs used
Read the detailed description

This study is a platform trial evaluating new drugs or combination of drugs in relapsed or refractory peripheral T-cell lymphomas via multiple sub-studies. For phase 1 sub-studies, at least 18 evaluable patients are required per each sub-study. For phase 2 sub-studies, 31 evaluable patients are required per sub-study.

Each sub-study has its own specificities:

  • Origina-ly-T: open-label phase 2 study evaluating the efficacy and safety of roginolisib in relapsed/refractory peripheral T-cells lymphoma. Study treatment will be administered until unacceptable toxicity, disease progression, subject/physician decision to withdraw, whichever happens first.
  • GolcAza: open-label phase 1 study to identify the maximum tolerated dose of golcadomide in association with oral 5-azacitidine and evaluate the efficacy and safety of the determined combination of oral 5-azacitidine and golcadomide in relapsed/refractory follicular helper T-cell lymphoma subjects. Subjects will receive golcadomide and oral 5-azacitidine until end of study or until disease progression, unacceptable toxicity, subject/physician decision to withdraw, whichever occurs first.
  • VenAza: open-label phase 2 study evaluatinf efficacy and safety of a combination of oral 5-azacitidine and venetoclax in relapse/refractory (R/R) follicular helper T-cell lymphoma participants. Study treatment will be administered until study end or until unacceptable toxicity, disease progression, participant/physician decision to withdrw, whichever occurs first.
03

Conditions studied

  • Peripheral T Cells Lymphoma (PTCL)
  • Follicular Helper T-Cell Lymphoma

Browse trials for

Keywords

  • lymphoma
  • peripheral T cells lymphoma
  • roginolisib
  • azacitidine
  • refractory peripheral T-cells lymphoma
  • relapsed peripheral T-cells lymphoma
  • golcadomide
  • Follicular Helper T-cell lymphoma
  • venetoclax
04

Who can participate

The criteria were revised on the registry on Nov 6, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. Subject who understood and voluntarily signed and dated an prior to any study-specific assessments/procedures being conducted;
  2. Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF);
  3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements;
  4. Subject with proven peripheral T-cell lymphoma according to the criteria of the WHO classification 2017 or 2022 (subjects with mycosis fungoides, Sezary syndrome, lymphoblastic or large granular lymphocytic lymphoma will be excluded). Tumor tissue (initial diagnosis or relapse) should be available for central pathology review and biological characterization;
  5. Subject in relapse/ situation;
  6. performance status 0 to 2, or 3 if thought to be related to lymphoma;
  7. Adequate bone marrow function as defined by:

    • ≥ 1,5 x 10\^9/L (≥ 1 x 10\^9/L if related to lymphoma)
    • ≥ 75 x 10\^9/L (≥ 50 x 10\^9/L if related to lymphoma)
    • ≥ 8 g/dL;
  8. Anticipated at least 3 months;
  9. Presence of disease specific criteria allowing response evaluation. Unless otherwise specified, such criteria include:

    a. Baseline fluorodeoxyglucose PET-scan demonstrating at least one positive (FDG-avid) lesion; b. and at least one bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension, or at least one bi-dimensionally measurable extra nodal lesion, defined as > 1.0 cm in its longest dimension;

  10. :

    • For women of (WOCBP): must have a negative result for pregnancy test, at screening and within 24 hours prior to initiating study treatment. The WOCBP agree to abstain from becoming pregnant or breastfeeding, to remain abstinent (from heterosexual intercourse) or use at least one highly effective method of contraception and to refrain from donating eggs, during the treatment period (including periods of treatment interruption) and for at least the delay described in the sub-protocol for the concerned molecules;
    • For men of : agreement to remain abstinent (refrain from heterosexual intercourse) or use at least a condom as method of contraception with a non-pregnant female partner of childbearing potential or a pregnant female partner, and to refrain from donating sperm, during the treatment period (including periods of treatment interruption), and for at least the delay described in the sub-protocol for the concerned molecules;
  11. Subject covered by a social security system;
  12. Subject who understands and speaks one of the country official languages unless local regulation authorizes independent translators;

    Additional inclusion criteria specific to Origina-ly-T sub-study:

  13. For anaplastic large cell lymphoma subjects: failed or ineligible or intolerant to brentuximab vedotin. For extranodal NK/T-cells lymphoma: failed or ineligible or intolerant to asparaginase-containing regimen;

Additional inclusion criteria specific to Golcaza sub-study:

13. Subject had local diagnosed (nodal) follicular helper T cell lymphoma according to WHO classification 2022 or ICC 2022 classification based on a surgical lymph node or needle core biopsy including any one of the following type:

  • angioimmunoblastic type (AITL)
  • follicular T cell type
  • not otherwise specified (NOS);

    14. ECOG performance status 0 to 1 (supersedes criterium 6 of the Master protocol);

    15. Subjects must have an (INR) \< 1.5 x and partial thromboplastin time (aPTT) \< 1.5 x ULN (for subjects not receiving therapy). Note: Subjects receiving therapy for a thromboembolic event that occurred > 3months prior to enrollment are eligible as long as they are on a stable regimen of anticoagulation with warfarin, low-molecular weight heparin, or other approved therapeutic anticoagulation or antiplatelet regimen;

    16. Contraception (supersedes criterium 10 of the Master protocol):

  • For women of childbearing potential (WOCBP): must have a negative result for pregnancy test, 10 to 14 days prior to initiating study treatment and within 24 hours prior to initiating study treatment. WOCBP agree to abstain from becoming pregnant or breastfeeding and to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one highly effective method of contraception , at least 28 days before the first dose of study treatment , during the treatment period (including periods of treatment interruption), and for at least 28 days after the last dose of golcadomide, and 6 months after the last dose of azacitidine. Women must refrain from donating eggs during this same period;
  • For men: during the treatment period (including periods of treatment interruption), and for at least 28 days after the last dose of golcadomide and 3 months after the last dose of oral 5-azacitidine male subjects must:

    • With female partners of childbearing potential: use a condom associated with a highly effective method of contraception or remain abstinent (refrain from heterosexual intercourse)
    • With pregnant female partners: use a condom or remain abstinent (refrain from heterosexual intercourse) Men must refrain from donating sperm during this same period;

Additional inclusion criteria specific to VenAza sub-study:

13. Participant had local diagnosed (nodal) follicular helper T cell lymphoma according to WHO classification 2022 or ICC 2022 classification based on a surgical lymph node biopsy or needle core biopsy including any one of the following type:

  • angioimmunoblastic type (AITL)
  • follicular T cell type
  • not otherwise specified (NOS);

    14. Contraception (supersedes criterium 10 of the Master protocol):

  • For women of childbearing potential (WOCBP): must have a negative result for pregnancy test, at screening and within 24 hours prior to initiating study treatment. The WOCBP agree to abstain from becoming pregnant or breastfeeding, to remain abstinent (refrain from heterosexual intercourse) or use at least one highly effective method of contraception, and to refrain from donating eggs, during the treatment period (including periods of treatment interruption), and up to 30 days after the participant's last dose of venetoclax and 6 months after the last dose of oral 5-azacitidine. f the female participant uses a hormonal contraceptive method (hormonal contraceptive pills or devices) as highly effective birth control method, a barrier method should be added.
  • For men of reproductive potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use at least a condom as method of contraception with a non-pregnant female partner of childbearing potential or a pregnant female partner (even if the male participant has undergone a successful vasectomy) and to refrain from donating sperm, during the treatment period (including periods of treatment interruption), and up to 30 days after the participant's last dose of venetoclax and 3 months after the last dose of oral 5-azacitidine.

Exclusion Criteria:

  1. Evidence of central nervous system involvement by lymphoma;
  2. Any significant medical conditions, laboratory abnormality or psychiatric illness likely to interfere with participation in this clinical study (according to the investigator's decision);
  3. Uncontrolled systemic fungal, bacterial, or viral infection;
  4. Known Virus (HCV) or active Virus (HBV) infection defined as subject with detectable viral load (respectively detectable viral RNA or detectable viral DNA);
  5. Active other than the one treated in this research, unless the subject has been free of the disease for 2 years (subjects with a history of a completely resected non-melanoma skin cancer or successfully treated for an in-situ carcinoma are eligible);
  6. Use of any standard or experimental anti-cancer drug therapy within 28 days or a minimum of 5 half-lives of the drug, whatever the shortest prior to first administration of study drug;.
  7. Subject taking within 14 days prior to first administration of study drug, unless administered at a cumulated dose equivalent of prednisone ≤ 20mg /day (within these 14 days);
  8. Subject with prior hematopoietic cell transplantation (auto-HCT) ≤ 3 months prior to starting product(s). If subject had autologous SCT (Stem Cell Transplant) > 3 months prior to the start of investigational product(s), any unresolved (Grade > 1) autologous SCT-related toxicity;
  9. Subject with prior allogeneic hematopoietic cell transplantation (allo-HCT) with either standard or reduced intensity conditioning ≤ 3 months prior to starting investigational product(s). If subject had allogeneic SCT > 3 months prior to the start of investigational product(s) and still has any unresolved situation including (Grade > 1) treatment-related toxicity and/or ongoing immunosuppressor therapy and/or more than mild (NIH consensus) chronic ;
  10. Subject with major surgery ≤ 14 days prior to starting investigational product(s). Subjects must have recovered from any effects of recent surgery;
  11. Subject who has received prior localized anticancer therapy (eg. radiotherapy [including palliative radiotherapy]) ≤ 14 days prior to starting investigational product(s);
  12. Known or suspected to active substance or to any of the ;
  13. Pregnant, planning to become pregnant, or lactating woman;
  14. Person deprived of his/her liberty by a judicial or administrative decision;

    Exclusion criteria specific to Origina-ly-T sub-study:

  15. Positive test at screening, with the following exception: individuals with a positive HIV test at screening are eligible provided they are stable on antiretroviral therapy for at least 4 weeks, have a ≥ 200/uL, have an undetectable viral load, and have not had a history of opportunistic infection attributable to HIV within the last 12 months
  16. Impaired renal function (calculated CKP-EPI, or Creatinine Clearance \< 30 ml/min) or impaired liver function tests (serum total level > 34 μmol/L), except in case of Gilbert's Syndrome, or documented liver or pancreatic involvement by lymphoma, serum transaminases ( or ALT) > 3 upper normal limits, unless elevated to up to 5 x ULN due to peripheral T-cells lymphoma);
  17. Significant cardiovascular disease [e.g., Objective Class C or D heart diseases (cf. Classes of Heart Failure \| American Heart Association)], myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina);
  18. Prior exposure to PI3Kdelta inhibitor;
  19. Known or suspected allergies, hypersensitivity, or intolerance to Roginolisib or its excipients;
  20. Inability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medications;
  21. Subjects with a diagnosis of cutaneous T-cell lymphoma (CTCL);
  22. Prior solid organ transplantation;

Exclusion criteria specific to GolcAza sub-study:

15. Evidence of positive HTLV1 serology;

16. Positive HIV test at screening, with the following exception: individuals with a positive HIV test at screening are eligible provided they are stable on antiretroviral therapy for at least 4 weeks, have a CD4 count ≥ 200/uL, have an undetectable viral load, and have not had a history of opportunistic infection attributable to HIV within the last 12 months;

17. Impaired renal function (calculated CKD-EPI, MDRD or Cockcroft-Gault Creatinine Clearance \< 30 ml/min) or impaired liver function tests (serum total bilirubin level > 34 μmol/L) except in case of Gilbert's Syndrome, or documented liver or pancreatic involvement by lymphoma, serum transaminases (AST or ALT) > 3 upper normal limits (except documented liver involvement by lymphoma);

18. Prior exposure to golcadomide;

19. Refractory to azacitidine;

20. Significant cardiovascular disease [e.g., Objective Class C or D heart diseases (cf. Classes of Heart Failure \| American Heart Association)], myocardial infarction ≤ 3 months prior to starting golcadomide, unstable angina pectoris ≤ 3 months prior to starting golcadomide), or complete left bundle branch or bifascicular block), congenital long syndrome, QTcF ≥ 470 msec on screening, persistent or clinically meaningful ventricular arrhythmias;

21. Received strong inhibitors, moderate CYP3A inhibitors, strong CYP3A inducers, moderate CYP3A inducers within 7 days prior to initiation of study treatment;

22. Vaccinated with live, attenuated vaccines within 6 months of enrollment;

23. Known or suspected allergies, hypersensitivity, or intolerance to azacitidine, golcadomide or its excipients;

24. Any known malabsorption syndrome or disease associated with malabsorption.

Exclusion criteria specific to VenAza sub-study:

15. Evidence of positive HTLV1 serology;

16. Positive HIV test at screening, with the following exception: individuals with a positive HIV test at screening are eligible provided they are stable on antiretroviral therapy for at least 4 weeks, have a CD4 count ≥ 200/uL, have an undetectable viral load, and have not had a history of opportunistic infection attributable to HIV within the last 12 months;

17. Impaired renal function (calculated CKD-EPI, MDRD or Cockcroft-Gault Creatinine Clearance \< 30 ml/min) or impaired liver function tests (serum total bilirubin level > 34 μmol/L) except in case of Gilbert's Syndrome, or documented liver or pancreatic involvement by lymphoma, serum transaminases (AST or ALT) > 3 upper normal limits (except documented liver involvement by lymphoma);

18. Prior exposure to venetoclax;

19. Refractory to azacitidine;

20. Significant cardiovascular disease [e.g., Objective Class C or D heart diseases (cf. Classes of Heart Failure \| American Heart Association)], myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina);

21. Received strong and moderate P-gp inhibitor and strong CYP3A inhibitors, moderate CYP3A inhibitors, strong CYP3A inducers, moderate CYP3A inducers within 7 days prior to initiation of study treatment.;

22. Vaccinated with live, attenuated vaccines within 6 months of enrolment;

23. Known or suspected allergies, hypersensitivity, or intolerance to azaciticine, venetoclax or their excipients;

24. Any known malabsorption syndrome or disease associated with malabsorption.

Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Origina-ly-T

    Open-label phase 2 sub-study to evaluate the efficacy and safety of roginolisib in relapsed/refractory peripheral T-cells lymphoma. Study treatment will be administered until unacceptable toxicity, disease progression, subject/physician decision to withdraw, whichever happens first. 31 evaluable patients needed.

    Drug: roginolisib

  • Experimental
    GolcAza

    Open-label phase 1 sub-study to identify the maximum tolerated dose of golcadomide in association with oral 5-azacitidine and evaluate the efficacy and safety of the determined combination of oral 5-azacitidine and golcadomide in relapsed/refractory follicular helper T-cell lymphoma subjects. Subjects will receive golcadomide and oral 5-azacitidine until end of study or until disease progression, unacceptable toxicity, subject/physician decision to withdraw, whichever occurs first. Minimum 18 evaluable patient required.

    Drug: golcadomide · Drug: azacitidine

  • Experimental
    VenAza

    Open-label phase 2 sub-study to evaluate the efficacy and safety of a combination of oral 5-azacitidine and venetoclax in refractory/relapse follicular helper T-cell lymphoma subjects. Subjects will receive venetoclax and oral 5-azacitidine until end of study or until unacceptable toxicity, disease progression, participant/physican decision to withdraw, whichever occurs first. 31 evaluable patients needed.

    Drug: azacitidine · Drug: Venetoclax

Interventions

06

What researchers measure

Primary outcomes

  1. Modified Progression-Free Survival

    mPFS

    Time frame: From enrollment to end of follow-up period of Origina-ly-T (= maximum 2 years after enrollment)

  2. Maximum Tolerated Dose

    MTD

    Time frame: From enrollment to end of treatment of sub-study GolcAza (= maximum 2 years from enrollment)

  3. Recommended Phase II Dose

    RP2D

    Time frame: From enrollment to end of treatment of sub-study GolcAza (= maximum 2 years from enrollment)

07

Study locations

19 of 20 sites recruiting
  • CHU D'ANGERS - Service des Maladies du Sang
    Angers, 49100, France
    Recruiting
    • Aline CLAVERT, Dr · Principal investigator
  • Institut d'Hématologie de Basse Normandie - Service Hématologie (CHU Hôpital Côte de Nacre)
    Caen, 14000, France
    Recruiting
    • Gandhi-Laurent DAMAJ, Pr · Principal investigator
  • CHU Estaing - Service Thérapie Cellulaire et Hématologie Clinique
    Clermont-Ferrand, 63100, France
    Recruiting
    • Olivier TOURNILHAC, Pr · Principal investigator
  • Hôpital Henri Mondor - Unité Hémopathies Lymphoïdes
    Créteil, 94000, France
    Recruiting
    • François LEMONNIER, Pr · Principal investigator
  • CHU Dijon Bourgogne - Service Hématologie Clinique
    Dijon, 21000, France
    Recruiting
    • Steeve CHEVREUX, Dr · Principal investigator
  • CHU de Grenoble - Service Hématologie
    La Tronche, 38700, France
    Recruiting
    • Sylvain CARRAS, Dr · Principal investigator
  • CH du Mans - Centre de Cancérologie de la Sarthe - Service Hématologie
    Le Mans, 72000, France
    Recruiting
    • Kamel LARIBI, Dr · Principal investigator
  • CHU de Lille - Hôpital Claude Huriez - Service des Maladies du Sang
    Lille, 59000, France
    Recruiting
    • Doriane CAVALIERI, Dr · Principal investigator
  • Institut Paoli Calmettes - Service Hématologie
    Marseille, 13009, France
    Not yet recruiting
    • Jean-Marc SCHIANO DE COLELLA, Dr · Principal investigator
  • CHU de Montpellier - Département d'Hématologie Clinique
    Montpellier, 34080, France
    Recruiting
    • Charles HERBAUX, Pr · Principal investigator
  • CHU de Nantes - Service Hématologie
    Nantes, 44000, France
    Recruiting
    • Benoit TESSOULIN, Dr · Principal investigator
  • Hôpital Necker - Service Hématologie Adultes
    Paris, 75015, France
    Recruiting
    • Morgane CHEMINANT, Dr · Principal investigator
  • CHU de Bordeaux - Hôpital Haut-Lévêque - Centre François Magendie - Service d'Hématologie et Thérapie Cellulaire
    Pessac, 33600, France
    Recruiting
    • François-Xavier GROS, Dr · Principal investigator
  • CHU Lyon-Sud - Hématologie Clinique
    Pierre-Bénite, 69310, France
    Recruiting
    • Emmanuel BACHY, Dr · Principal investigator
  • CHU de Poitiers - Hôpital de la Milétrie - Service d'Oncologie Hématologique et Thérapie Cellulaire
    Poitiers, 86000, France
    Recruiting
    • Stéphanie GUIDEZ, Dr · Principal investigator
  • CHU Pontchaillou - Hématologie Clinique
    Rennes, 35000, France
    Recruiting
    • Roch HOUOT, Pr · Principal investigator
  • Centre Henri Becquerel - Service Hématologie
    Rouen, 76000, France
    Recruiting
    • Vincent CAMUS, Dr · Principal investigator
  • Institut de Cancérologie et d'Hématologie Universitaire de Saint-Étienne - Service Hématologie
    Saint-Etienne, 42000, France
    Recruiting
    • Jérôme CORNILLON, Dr · Principal investigator
  • CH de la Côte Basque - Service Hématologie
    Saint-Jean-de-Luz, 64500, France
    Recruiting
    • Sophie BERNARD, Dr · Principal investigator
  • CHRU Nancy - Hôpital Brabois - Service Hématologie
    Vandœuvre-lès-Nancy, 54500, France
    Recruiting
    • Charline MOULIN, Dr · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Apr 2028, 32 months after the start.

Of 77 non-industry phase 1/2 interventional studies under Lymphoma, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 133. This study's planned 32 months is below that.

Counting every sponsor, half of 143 studies reached it within 74 months; a quarter within 48 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2025
First posted
Jun 12, 2025
StartActual
Aug 20, 2025
Primary completionEst.
Apr 2028
CompletionEst.
Jan 2030
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed. 6 sites changed recruiting status (6 now recruiting)
Show 6 sites
  • CHU Estaing - Service Thérapie Cellulaire et Hématologie Clinique · Clermont-Ferrand, FranceNot yet recruiting→Recruiting
  • CHU de Grenoble - Service Hématologie · La Tronche, FranceNot yet recruiting→Recruiting
  • CH du Mans - Centre de Cancérologie de la Sarthe - Service Hématologie · Le Mans, FranceNot yet recruiting→Recruiting
  • CHU de Bordeaux - Hôpital Haut-Lévêque - Centre François Magendie - Service d'Hématologie et Thérapie Cellulaire · Pessac, FranceNot yet recruiting→Recruiting
  • CHU Pontchaillou - Hématologie Clinique · Rennes, FranceNot yet recruiting→Recruiting
  • CHRU Nancy - Hôpital Brabois - Service Hématologie · Vandœuvre-lès-Nancy, FranceNot yet recruiting→Recruiting
Show site
  • CHU D'ANGERS - Service des Maladies du Sang · Angers, France
Show 1 removed
  • Institut de Cancérologie Strasbourg Europe - Service Hématologie · Strasbourg, France
Nov 6, 2026
Enrollment
49→80
Nov 6, 2026
Eligibility
1 criterion edited, 19 added, 1 removed
What changed in the criteria
  • RemovedBaseline fluorodeoxyglucose PET-scan demonstrating at least one positive (FDG-avid) lesion;
  • EditedBaseline fluorodeoxyglucose PET-scan demonstrating at least one positive (FDG-avid) lesion; b. and at least one bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension, or at least one bi-dimensionally measurable extra nodal lesion, defined as > 1.0 cm in its longest dimension;
  • AddedAdditional inclusion criteria specific to VenAza sub-study:
  • Added13. Participant had local diagnosed (nodal) follicular helper T cell lymphoma according to WHO classification 2022 or ICC 2022 classification based on a surgical lymph node biopsy or needle core biopsy including any one of the following type:
  • Addedangioimmunoblastic type (AITL)
  • Addedfollicular T cell type
  • Addednot otherwise specified (NOS);
  • Added14. Contraception (supersedes criterium 10 of the Master protocol):
  • AddedFor women of childbearing potential (WOCBP): must have a negative result for pregnancy test, at screening and within 24 hours prior to initiating study treatment. The WOCBP agree to abstain from becoming pregnant or breastfeeding, to remain abstinent (refrain from heterosexual intercourse) or use at least one highly effective method of contraception, and to refrain from donating eggs, during the treatment period (including periods of treatment interruption), and up to 30 days after the participant's last dose of venetoclax and 6 months after the last dose of oral 5-azacitidine. f the female participant uses a hormonal contraceptive method (hormonal contraceptive pills or devices) as highly effective birth control method, a barrier method should be added.
  • AddedFor men of reproductive potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use at least a condom as method of contraception with a non-pregnant female partner of childbearing potential or a pregnant female partner (even if the male participant has undergone a successful vasectomy) and to refrain from donating sperm, during the treatment period (including periods of treatment interruption), and up to 30 days after the participant's last dose of venetoclax and 3 months after the last dose of oral 5-azacitidine.
  • AddedExclusion criteria specific to VenAza sub-study:
  • Added15. Evidence of positive HTLV1 serology;
  • Added16. Positive HIV test at screening, with the following exception: individuals with a positive HIV test at screening are eligible provided they are stable on antiretroviral therapy for at least 4 weeks, have a CD4 count ≥ 200/uL, have an undetectable viral load, and have not had a history of opportunistic infection attributable to HIV within the last 12 months;
  • Added17. Impaired renal function (calculated CKD-EPI, MDRD or Cockcroft-Gault Creatinine Clearance < 30 ml/min) or impaired liver function tests (serum total bilirubin level > 34 μmol/L) except in case of Gilbert's Syndrome, or documented liver or pancreatic involvement by lymphoma, serum transaminases (AST or ALT) > 3 upper normal limits (except documented liver involvement by lymphoma);
  • Added18. Prior exposure to venetoclax;
  • Added19. Refractory to azacitidine;
  • Added20. Significant cardiovascular disease [e.g., Objective Class C or D heart diseases (cf. Classes of Heart Failure | American Heart Association)], myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina);
  • Added21. Received strong and moderate P-gp inhibitor and strong CYP3A inhibitors, moderate CYP3A inhibitors, strong CYP3A inducers, moderate CYP3A inducers within 7 days prior to initiation of study treatment.;
  • Added22. Vaccinated with live, attenuated vaccines within 6 months of enrolment;
  • Added23. Known or suspected allergies, hypersensitivity, or intolerance to azaciticine, venetoclax or their excipients;
  • Added24. Any known malabsorption syndrome or disease associated with malabsorption.
Nov 6, 2026
Interventions
Added Drug: Venetoclax. Arms added: VenAza
Nov 6, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Institut Paoli Calmettes - Service Hématologie · Marseille, FranceContact person changed (no phone or email listed)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    1 site added, 1 site removed. 6 sites changed recruiting status (6 now recruiting)
    Show 6 sites
    • CHU Estaing - Service Thérapie Cellulaire et Hématologie Clinique · Clermont-Ferrand, FranceNot yet recruiting→Recruiting
    • CHU de Grenoble - Service Hématologie · La Tronche, FranceNot yet recruiting→Recruiting
    • CH du Mans - Centre de Cancérologie de la Sarthe - Service Hématologie · Le Mans, FranceNot yet recruiting→Recruiting
    • CHU de Bordeaux - Hôpital Haut-Lévêque - Centre François Magendie - Service d'Hématologie et Thérapie Cellulaire · Pessac, FranceNot yet recruiting→Recruiting
    • CHU Pontchaillou - Hématologie Clinique · Rennes, FranceNot yet recruiting→Recruiting
    • CHRU Nancy - Hôpital Brabois - Service Hématologie · Vandœuvre-lès-Nancy, FranceNot yet recruiting→Recruiting
    Show site
    • CHU D'ANGERS - Service des Maladies du Sang · Angers, France
    Show 1 removed
    • Institut de Cancérologie Strasbourg Europe - Service Hématologie · Strasbourg, France
    Enrollment 49→80
    Eligibility 1 criterion edited, 19 added, 1 removed
    What changed in the criteria
    • RemovedBaseline fluorodeoxyglucose PET-scan demonstrating at least one positive (FDG-avid) lesion;
    • EditedBaseline fluorodeoxyglucose PET-scan demonstrating at least one positive (FDG-avid) lesion; b. and at least one bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension, or at least one bi-dimensionally measurable extra nodal lesion, defined as > 1.0 cm in its longest dimension;
    • AddedAdditional inclusion criteria specific to VenAza sub-study:
    • Added13. Participant had local diagnosed (nodal) follicular helper T cell lymphoma according to WHO classification 2022 or ICC 2022 classification based on a surgical lymph node biopsy or needle core biopsy including any one of the following type:
    • Addedangioimmunoblastic type (AITL)
    • Addedfollicular T cell type
    • Addednot otherwise specified (NOS);
    • Added14. Contraception (supersedes criterium 10 of the Master protocol):
    • AddedFor women of childbearing potential (WOCBP): must have a negative result for pregnancy test, at screening and within 24 hours prior to initiating study treatment. The WOCBP agree to abstain from becoming pregnant or breastfeeding, to remain abstinent (refrain from heterosexual intercourse) or use at least one highly effective method of contraception, and to refrain from donating eggs, during the treatment period (including periods of treatment interruption), and up to 30 days after the participant's last dose of venetoclax and 6 months after the last dose of oral 5-azacitidine. f the female participant uses a hormonal contraceptive method (hormonal contraceptive pills or devices) as highly effective birth control method, a barrier method should be added.
    • AddedFor men of reproductive potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use at least a condom as method of contraception with a non-pregnant female partner of childbearing potential or a pregnant female partner (even if the male participant has undergone a successful vasectomy) and to refrain from donating sperm, during the treatment period (including periods of treatment interruption), and up to 30 days after the participant's last dose of venetoclax and 3 months after the last dose of oral 5-azacitidine.
    • AddedExclusion criteria specific to VenAza sub-study:
    • Added15. Evidence of positive HTLV1 serology;
    • Added16. Positive HIV test at screening, with the following exception: individuals with a positive HIV test at screening are eligible provided they are stable on antiretroviral therapy for at least 4 weeks, have a CD4 count ≥ 200/uL, have an undetectable viral load, and have not had a history of opportunistic infection attributable to HIV within the last 12 months;
    • Added17. Impaired renal function (calculated CKD-EPI, MDRD or Cockcroft-Gault Creatinine Clearance < 30 ml/min) or impaired liver function tests (serum total bilirubin level > 34 μmol/L) except in case of Gilbert's Syndrome, or documented liver or pancreatic involvement by lymphoma, serum transaminases (AST or ALT) > 3 upper normal limits (except documented liver involvement by lymphoma);
    • Added18. Prior exposure to venetoclax;
    • Added19. Refractory to azacitidine;
    • Added20. Significant cardiovascular disease [e.g., Objective Class C or D heart diseases (cf. Classes of Heart Failure | American Heart Association)], myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina);
    • Added21. Received strong and moderate P-gp inhibitor and strong CYP3A inhibitors, moderate CYP3A inhibitors, strong CYP3A inducers, moderate CYP3A inducers within 7 days prior to initiation of study treatment.;
    • Added22. Vaccinated with live, attenuated vaccines within 6 months of enrolment;
    • Added23. Known or suspected allergies, hypersensitivity, or intolerance to azaciticine, venetoclax or their excipients;
    • Added24. Any known malabsorption syndrome or disease associated with malabsorption.
    Interventions Added Drug: Venetoclax. Arms added: VenAza
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Institut Paoli Calmettes - Service Hématologie · Marseille, FranceContact person changed (no phone or email listed)
    + 4 other changes: index terms, verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07018752
Lead sponsor
The Lymphoma Academic Research Organisation
Collaborators
iOnctura, AbbVie, Bristol-Myers Squibb
Responsible party
Sponsor
First posted
Jun 12, 2025
Start date
Aug 20, 2025
Primary completion
Apr 2028 (estimated)
Completion
Jan 2030 (estimated)
Last update
Nov 12, 2026

Study contacts

Clinical Project Manager
Contact
platform@lysarc.org
+33 4 72 66 93 33
François LEMONNIER, Pr
principal investigator · Hôpital Henri Mondor - Lymphoid Malignancies Unit

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Roginolisib · Golcadomide · Azacitidine · Venetoclax

Start the discussion